Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,035 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,952 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00878254 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | completed | Phase 2 | 25 | University of MiamiOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05583318 | Living Conditions After Non-Hodgkin's Lymphoma in France(LymphoVie 2) | completed | — | 1,570 | Centre Hospitalier Universitaire DijonOTHER | 1 | Jul 23, 2025 |
| clinicaltrials |
| NCT06602674 | PET/CT-Based Image Analysis and Machine Learning of Hypermetabolic Pulmonary Lesions | completed | — | 647 | Ruijin HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03112174 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)(SYMPATICO) | completed | Phase 3 | 366 | Pharmacyclics LLC.INDUSTRY | 17 | Jul 22, 2025 | clinicaltrials |
| NCT04473911 | Haplo Peripheral Blood Sct In GVHD Prevention | completed | Phase 1 | 25 | Zachariah Michael DeFilippOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05011097 | A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 20 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06061302 | Multiple Myeloma Yoga Pilot Study | completed | N/A | 31 | University of ArizonaOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT02956382 | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT01051635 | A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT04833504 | Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma | completed | — | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT03144674 | A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) | completed | Phase 2 | 110 | Incyte CorporationINDUSTRY | 12 | Jul 11, 2025 | clinicaltrials |
| NCT05019144 | Telemedicine Optimized Burn Intervention(TOBI) | completed | N/A | 130 | Medical University of South CarolinaOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT01996865 | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.(MAGNIFY) | completed | Phase 3 | 503 | CelgeneINDUSTRY | 3 | Jul 10, 2025 | clinicaltrials |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 523 | Janssen Research & Development, LLCINDUSTRY | 28 | Jul 8, 2025 | clinicaltrials |
| NCT02329080 | New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | completed | Phase 2 | 79 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jul 8, 2025 | clinicaltrials |
| NCT04618081 | Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL) | completed | — | 151 | CelgeneINDUSTRY | 1 | Jul 8, 2025 | clinicaltrials |
| NCT02722668 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04669210 | PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT(PTCyRuxo) | completed | Phase 2 | 128 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06511869 | AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) | completed | Phase 2 | 48 | Dizal PharmaceuticalsINDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03884556 | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | completed | Phase 1 | 56 | Trishula Therapeutics, Inc.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT02821793 | Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer(PRIORITY) | completed | — | 346 | Institut BergoniéOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03133221 | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | completed | Phase 2 | 17 | University of Maryland, BaltimoreOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07041827 | Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma(CLARITY) | completed | — | 217 | The Netherlands Cancer InstituteOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT02765854 | Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement | completed | Phase 2 | 70 | Emory UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04400071 | Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment | completed | N/A | 192 | Indiana UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07039383 | A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients(KareALL) | completed | — | 79 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT02358980 | Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma & Cast Nephropathy(KEEPER) | completed | — | 5 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jun 25, 2025 | clinicaltrials |
| NCT02546167 | CART-BCMA Cells for Multiple Myeloma | completed | Phase 1 | 25 | University of PennsylvaniaOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT01995669 | Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT03713294 | Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma | completed | Phase 2 | 37 | Mayo ClinicOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT00001337 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 348 | National Cancer Institute (NCI)NIH | 1 | Jun 22, 2025 | clinicaltrials |
| NCT02446964 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia | completed | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT02750670 | Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT03900598 | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 226 | Janssen Research & Development, LLCINDUSTRY | 12 | Jun 22, 2025 | clinicaltrials |
| NCT00001379 | Treatment and Natural History Study of Lymphomatoid Granulomatosis | completed | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03770260 | Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment | completed | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03742258 | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT01359592 | S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 159 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06151717 | A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma | completed | — | 50 | Mayo ClinicOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT00674479 | INCB018424 in Patients With Advanced Hematologic Malignancies | completed | Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05827107 | Skin Barrier and Microbiome of CTCL Patients | completed | — | 43 | Centre for Human Drug Research, NetherlandsOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT00476190 | ALL Adult Consortium Trial: Adult ALL Trial | completed | Phase 2 | 112 | Dana-Farber Cancer InstituteOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT01290302 | Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza | completed | Phase 1 | 38 | American Regent, Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06709248 | Feasibility of a Life Coping Program: A Study Protocol(LifeCOPE) | completed | N/A | 54 | Haukeland University HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT02303392 | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | completed | Phase 1 | 34 | Jennifer WoyachOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT02871219 | Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT00112827 | Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | City of Hope Medical CenterOTHER | 1 | Jun 6, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jul 23, 2025source: clinicaltrials